Cannabis Science (CBIS) Retains Cohen Grassroots Research Firm To Initiate Coverage Beginning With A 115-Page Analytical Report
COLORADO SPRINGS, Colo., March 18, 2015 /PRNewswire/ -- Cannabis Science, Inc. (OTCQB: CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, today announced that Cohen Grassroots Research, Inc. (CGR), Wall Street's leading independent micro-cap and cannabis research firm, has been retained by the Company to initiate intricate analytical coverage of the Company.
According to the 115-page initial Research Coverage Report, Cannabis Science, Inc. (OTC QB: CBIS) is a pharmaceutical and cannabis medical portfolio company researching and commercializing cannabis-based medical applications for multi-billion dollar markets. The Company is formulating treatments for skin cancer (CS-S/BCC-1); for HIV (CS-S/BCC-l); and neurological disorders (CS-NEURO-1), including drug-resistant strains of Kaposi's Sarcoma, PTSD and other infectious diseases using phytocannabinoid-based therapies. The Company is dedicated to providing quality, innovative treatments to patients for a variety of critical ailments.
In a few short months, the report states, new CEO and President Raymond C. Dabney has restructured and redirected the business model, adding revenue-producing businesses and expanding the CBIS footprint worldwide. CBIS has begun pre-investigational studies in pursuit of filing New Drug applications with the U.S. Food and Drug Administration (FDA) for CS-NEURO-1, CS-TATI -1, and CS-S/BCC-1. CBIS has raised funds and is collaborating with partners to share synergies in R&D and commercialization.
"Our estimates forecast revenues to grow from $0.1 million in FYE December 31, 2015 to approximately $64.52 million by FYE 2020. To meet our forecasts, the Company will need to raise $14.0 million in equity capital in the next couple of years to meet its capital requirements. Based on these projections and assuming the Company raises the required capital, the Cohen Target Price is $0.19, 268.9% higher than the current price," said D. Paul Cohen, President & CEO of Cohen Grassroots Research, Inc.
To formulate its price target, Cohen Grassroots Research performed an in-depth independent research analysis of CBIS, including five-year financial and valuation projections. The report is available at the Company website under the Investors information tab or click here:
http://www.cannabisscience.com/downloads/cbis-analyst-report_cohengrassrootsresearch_03-14-2015.pdf
or
www.cohenresearch.com and www.cohengrassroots.com
CBIS is the cannabis industry's pure stock, analytical coverage will be on a quarterly basis for the coming year. The decision to provide this type of analytical coverage is based on the need to articulate the progress of the Company, professionally, in a timely manner, to the public. The Company's many cannabinoid drug development initiatives underway internationally and the demand is growing expotentially. Cannabinoids are classified as a controlled substance under the Federal Controlled Substances Act of 1970.
Twenty-seven states plus the District of Columbia have some form of medical cannabis regulations in place. Growing support for legalization has led to a number of companies entering the market. The report contends a large market size and share will provide CBIS with significant growth opportunities and the ability to treat patients in need. In addition, the Company's experienced management team has built strong partnerships in an estimated $2.7 billion medical cannabis market. Under Dabney's leadership, multi-use compounds, solid R&D and continual innovation are targeted at developing new compounds in an exciting and medically-significant growth market, the report concludes.
About Cohen Grassroots Research, Inc.
Cohen Grassroots Research, Inc. is Wall Street's leading independent micro-cap, small-cap and cannabis research firm. The firm concentrates on emerging companies with strong management teams focused on shareholder value and sustainable competitive advantage. CGR, led by highly respected and well-known security analyst, D. Paul Cohen, highlights the Company's market opportunity, technology, management, competition and other key differentiators that may affect their long-term and short-term valuation. GRRD focuses on those public companies that lack or have minimal Wall Street IR research analyst coverage. CGR research reports are commissioned and paid for by the companies covered, or by third parties.
For more information, visit www.cohengrassroots.com.
The Cohen Grassroots Research disclaimer states: This report/release is for informational purposes only. All information contained herein is based on public information. CGR complies with securities laws, regulations and ethical standards as related to our legal and compliance requirements. Do your own research.
Cohen Compensation Statement
Because we receive compensation for CGR's dissemination of the Information, our publicly disseminated publications should not be regarded in any manner whatsoever as independent. CGR is sometimes paid for documents and distribution in cash, stock, Rule 144 stock, warrants, options or other securities in lieu of or in addition to CGR's stated compensation schedule. CGR services and documents rendered are not related to, connected to, nor are they contingent on a client's stock price performance. This compensation and ownership of securities of a client's common stock constitutes a conflict of interest as to our ability to remain objective in our communication regarding our profiled companies. More information can be received from our client company's website. The majority of our assignments are for 30 days. We may write reports or promote a given company on other occasions. The Company has paid 3,500,000 shares of Rule 144 common stock and $2,500 in compensation for this commercial advertisement program. This document shall not be copied and is copyrighted by Cohen Grassroots Research Inc. and D. Paul Cohen
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.